74. 下垂体性PRL分泌亢進症 Prolactin secreting pituitary adenoma Clinical trials / Disease details
臨床試験数 : 19 / 薬物数 : 28 - (DrugBank : 10) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03038308 (ClinicalTrials.gov) | September 16, 2016 | 30/1/2017 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability | Hyperprolactinemia;Prolactinoma | Drug: Ropinirole | Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active, not recruiting | 18 Years | 70 Years | All | 23 | Phase 1/Phase 2 | United States |